Now that regulations are easing on psychedelic drugs, which used to be classified as Schedule 1 drugs, more research can be conducted into the efficacy of their treatment of certain psychological disorders.

Because of the stigmatization of natural substances such as mushrooms and marijuana, many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festivalgoers. Yet, they may one day be used to treat disorders ranging from social anxiety to depression, according to new research. New research which is being more widely accepted as public support of the war on drugs wanes.

The research that is available shows that psychedelics can be effective in treating certain mental health ailments, such as PTSD. “Combined with psychotherapy, some psychedelic drugs like MDMA (commonly known as exctasy), psilocybin, and ayahuasca may improve symptoms of anxiety, depression and post-traumatic stress disorder,” said Cristina L. Magalhaes, PhD, of Alliant International University Los Angeles, and co-chair of a symposium on psychedelics and psychotherapy. “More research and discussion are needed to understand the possible benefits of these drugs, and psychologists can help navigate the clinical, ethical and cultural issues related to their use.”

MDMA is actually beginning its third and final phase of clinical trials in an effort to win Food and Drug Administration approval for treatment of post-traumatic stress disorder, said Adam Snider, MA, of Alliant International University Los Angeles, and co-chair of the symposium. Findings from one study presented at the symposium have even suggested that symptoms of social anxiety in autistic adults may be treatable with a combination of psychotherapy and MDMA.

Until recently, research has been largely stalled since the ban on psychedelics which happened back in the late 1960s. As more restrictions on some of these types of substances are removes, more research will be conducted. As of now, more and more people are jumping on board with the research into “magic mushrooms” and are supportive of studies conducted on other psychedelics.

Champignon Brands (SHRMF), which is named after a type of edible mushroom, is one of those companies that is pursuing the development and commercialization of rapid onset treatments using psychedelics. These treatments are often capable of improving health outcomes of ailments such as depression and post-traumatic stress disorder (PTSD). The company is also looking into being able to use these novel molecules to treat substance and alcohol use disorders.

Americans are making a dramatic shift to more natural treatments, as the drugs currently on the market are pricey and often come with disastrous side effects. Research into previously banned psychedelics will go a long a way to help those who are suffering.

The “shroom boom” is making its way through our society and it’s a wonderful thing to look forward to. Real, in depth, natural solutions to common problems are in high demand, and Champignon Brands is going to continue to deliver the solutions it can.

Disclosure/Disclaimer:
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

Never base any decision off of our emails. Wealth Research Group stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Wealth Research Group LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites.

Please read our full disclaimer at WealthResearchGroup.com/disclaimer